NewsNovo
For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss, with eligible beneficiaries paying a $50 monthly copay.
The move marks a structural shift in the federal health insurance program's treatment of obesity, extending coverage to a drug class previously reimbursed only when prescribed for other indications such as diabetes.
What Changed — and Why It Matters The distinction in this policy is the phrase "solely for weight loss." Until now, Medicare coverage of GLP-1 medications depended on a co-occurring condition the drugs were already approved to treat.
The new program carves out a standalone reimbursement path for weight management, which broadens the eligible population considerably — though the program sets specific eligibility criteria that beneficiaries must meet.
Keep reading